HC Wainwright Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX)

Equities research analysts at HC Wainwright assumed coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) in a research note issued to investors on Thursday, Zacks reports. The firm set a “strong-buy” rating on the stock. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.35) EPS and Q4 2027 earnings at ($0.32) EPS.

A number of other research analysts have also weighed in on AMLX. Guggenheim raised their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Tuesday. Mizuho increased their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Amylyx Pharmaceuticals in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $44.14.

Amylyx Pharmaceuticals Stock Up 6.8%

Shares of Amylyx Pharmaceuticals stock traded up $1.88 during mid-day trading on Thursday, reaching $29.50. 1,860,529 shares of the stock traded hands, compared to its average volume of 1,324,934. The stock has a market capitalization of $3.29 billion, a PE ratio of -20.49 and a beta of -0.09. The business has a 50-day moving average of $30.00 and a 200 day moving average of $20.41. Amylyx Pharmaceuticals has a fifty-two week low of $10.83 and a fifty-two week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.38). On average, equities research analysts expect that Amylyx Pharmaceuticals will post -1.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director M Jr sold 30,000 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $27.70, for a total transaction of $831,000.00. Following the transaction, the director owned 782,881 shares in the company, valued at approximately $21,685,803.70. This trade represents a 3.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Camille Bedrosian sold 10,028 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.40, for a total value of $324,907.20. Following the transaction, the insider owned 278,064 shares in the company, valued at approximately $9,009,273.60. The trade was a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 60,374 shares of company stock worth $1,815,257 in the last three months. Company insiders own 10.90% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of AMLX. GAMMA Investing LLC boosted its position in shares of Amylyx Pharmaceuticals by 163.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,139 shares of the company’s stock valued at $33,000 after acquiring an additional 706 shares during the last quarter. ProShare Advisors LLC increased its position in Amylyx Pharmaceuticals by 10.7% during the third quarter. ProShare Advisors LLC now owns 17,360 shares of the company’s stock worth $505,000 after purchasing an additional 1,675 shares during the last quarter. Arizona State Retirement System increased its position in Amylyx Pharmaceuticals by 9.5% during the second quarter. Arizona State Retirement System now owns 19,825 shares of the company’s stock worth $356,000 after purchasing an additional 1,726 shares during the last quarter. KBC Group NV acquired a new stake in Amylyx Pharmaceuticals during the first quarter worth about $26,000. Finally, State of Wyoming purchased a new position in Amylyx Pharmaceuticals during the second quarter worth about $40,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals News Summary

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $55 price target, while forecasting quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. The rating and target may support investor optimism. Analyst estimates and rating
• Neutral Sentiment: Amylyx reported a Q3 2026 loss of $0.38 per share, matching the consensus estimate. The in-line result was not a positive earnings surprise. Third-quarter financial results
• Neutral Sentiment: The company’s Q3 2026 earnings-call transcript was published, but the provided coverage does not detail additional announcements or outlook changes from the call. Q3 2026 earnings-call transcript

About Amylyx Pharmaceuticals